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Summary Previous studies have shown that groups of cancer sub-specialists differ in their stated willingness
to undergo treatment for diseases lying within their area ofexpertise. In order to learn whether oncologists feel
similarly about other forms of cancer, medical, radiation, and surgical oncologists were asked to fill out a
questionnaire indicating whether they would be willing to undergo either chemotherapy or radiation therapy
for a variety of common malignancies, or recommend them to a spouse or sibling. Subjects were also asked
whether they would undertake an experimental therapy (interleukin-2) for any of three malignancies, or
recommend such treatment to a spouse or relative. Fifty-one oncologists (14 radiation oncologists, 14 surgical
oncologists, and 23 medical oncologists) were recruited from the staff of four university teaching hospitals.
Although they agreed about accepting or declining therapy for some examples, there was considerable
heterogeneity in their responses. In only 37% of the 30 cases involving standard therapies did >85% of the
oncologists agree that they would accept or refuse therapy. Only some of the variation of the responses could
be attributed to the sub-specialty orientation of the oncologists. Physicians were as willing to recommend
standard therapies for themselves as a spouse or sibling. Physicians were also divided in their opinion about
whether they would accept a particular experimental therapy if diagnosed with one of three neoplasms. They
were significantly more likely, however, to recommend it for a spouse or sibling than to accept it for
themselves.
Variation in the proportion of patients who receive anti-cancer therapies may relate, in part, to differences
in opinion concerning the worth of such therapies among oncologists or primary physicians. This study shows
that oncologists are quite heterogeneous with regard to their personal preferences for anti-cancer treatments
for a variety of malignancies. Further studies are required to learn if such attitudes (among oncologists or
primary physicians) directly affect the administration of such therapies.
It is well recognised that there are variations in the delivery
of medical care in different regions of the country and across
different segments of the population (Wennberg, 1986). The
limited data available suggest that all patients with cancer are
not treated alike, but only a few factors have been identified
that may explain this, such as the age of the patient (Samet
et al., 1986; Mor et al., 1985; Greenfield et al., 1987; Grover
et al., 1989) or their socioeconomic status (Greenberg et al.,
1988). Because cancer presents a series of complex, threaten-
ing issues for patients and physicians alike, characteristics
and personal values of physicians may play a role in deter-
mining who receives treatment. This idea is supported, in the
setting of a clinical trial, by the work of Taylor and col-
leagues (Taylor et al., 1984) who documented that low rates
of patient enrollment in a surgical trial for breast cancer
could not be attributed to medical, scientific, or procedural
issues, but to physician characteristics and values. Other
evidence is available to suggest that physician beliefs, pre-
ferences, and perceptions may be important determinants of
how they talk to, as well as treat their patients (Hunter et al.,
1987; Wennberg et al., 1988; Argyle et al., 1989; Kong et al.,
1986). In addition, surveys of physicians have documented
considerable variability in physicians' stated willingness to
undergo specific forms of therapy for lung and genitourinary
malignancies (Mackillop et al., 1987; Moore et al., 1988).
Physicians' differing personal opinions about cancer treat-
ments might well affect the enthusiasm with which they
recommend such treatments to patients. Since examination of
the rates of administration of such treatments would not
allow us to distinguish the contribution of physician-related
values from those of patients, we conducted a pilot study to
detennine whether differences in physician opinions about
the values of therapy could be documented for a range of
malignancies. We asked cancer specialists as a particularly
knowledgeable groups of physicians to consider whether they
would untake standard and experimental treatments if diag-
nosed themselves with a number of different forms of cancer.
In addition, we asked them to consider whether they would
recommend these therapies to a spouse or sibling to deter-
mine whether physicians' recommendations might differ from
what they personally believe to be the best course of action,
in this simulated setting.
Methods
Interviews with 51 oncologists (14 surgical oncologists, 14
radiation therapists, and 23 medical oncologists) were con-
ducted during the latter half of 1987. All practiced in teach-
ing hospitals affiliated with Harvard Medical School (Beth
Israel Hospital, Brigham and Women's Hospital, Dana-
Farber Cancer Institute, and the Massachusetts General Hos-
pital) and had a mean age of 40.1 years; seven were women
(Table I). The sample is therefore a highly selected one,
chosen primarily to provide a comparable number of radia-
tion, surgical, and medical oncologists. At the completion of
the interview a questionnaire was given to each participant.
The responses to those questions relating to cancer treatment
are reported here. (The results of the interview and physi-
cians' responses to other questions are reported separately
(Good et al., 1990).) All subjects completed the question-
naire, most while the interviewer was still present, the
remainder within one week. Physicians were asked to indicate
whether they would choose therapy for themselves if they
had each of a number of defined malignancies, listed in
Tables Ila and b, using a five point scale. Values assigned to
Table I Sample characteristics
Radiation Surgical Medical
oncologists oncologists oncologists
Total 14 14 23
Mean age, years 39.5 44.9 34.4
Mean years since medical school 12.4 19.4 9.8
Average number of patients seen 33 33 28
each week
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Table II Oncologists' willingness to take anti-cancer therapies
Probably or Probably or Group Intergroup
definitely no Uncertain definitelyyes mean variation
% % % score P
a Chemotherapyfor:
Hodgkin's disease, stage IV 0 2 98 4.80±0.45 0.04
Diffuse histiocytic lymphoma, stage III-IV 0 6 94 4.68±0.59 0.001
Acute lymphocytic lymphoma 2 4 94 4.76±0.62 NS
Multiple myeloma 0 6 94 4.51±0.61 0.001
Non-seminomatous testicular cancer, stage III 0 10 90 4.72±0.64 NS
Limited stage small cell lung carcinoma 6 6 88 4.46±0.86 0.002
Metastatic breast carcinoma (to liver) 6 14 80 4.04±0.99 NS
Ovarian cancer, stage III 8 14 78 4.04± 1.3 NS
Extensive stage small cell lung carcinoma 20 8 72 3.84± 1.2 NS
Metastatic gastric carcinoma (to liver) 53 16 31 2.71 ± 1.3 NS
Non-small cell lung carcinoma, stage III 53 20 27 2.63± 1.2 0.003
Unresectable pancreatic cancer 71 11 18 2.22± 1.1 NS
Glioblastoma multiforme (brain) 55 28 17 2.43± 1.2 NS
Metastatic melanoma (to lung) 77 12 11 1.96± 1.1 NS
Colon cancer, resectable 84 8 8 1.80± 1.1 NS
b Radiation therapyfor:
Hodgkin's disease, stage I-II 0 2 98 4.82±0.43 NS
Resected rectal cancer, stage B3-C3 0 4 96 4.59±0.57 NS
Multiple myeloma (to site of bony pain) 2 2 96 4.67±0.62 NS
Limited stage small cell lung carcinoma 8 6 86 4.20± 1.0 0.02
Testicular seminoma, stage II 4 12 84 4.35±0.91 NS
Glioblastoma multiforme 10 10 80 4.12± 1.0 NS
Non-small cell lung carcinoma, stage III 16 8 76 3.76± 1.1 NS
Primary breast cancer 13 14 73 3.92± 1.3 NS
Diffuse histiocytic lymphoma, stage I 26 16 58 3.70± 1.3 NS
Ovarian cancer, stage II 40 15 45 2.86± 1.5 0.001
Locally advanced gastric cancer 53 8 39 2.80± 1.2 NS
Unresectable pancreatic cancer 61 8 31 2.41 ± 1.3 NS
Resected colon cancer, stage B3 C3 59 14 27 2.51 ± 1.3 0.001
Extensive stage small cell lung carcinoma 61 16 23 2.49± 1.2 NS
Metastatic melanoma (to lung) 90 4 6 1.65±0.82 NS
each response (definitely no = 1, probably no = 2, uncer-
tain = 3, probably yes = 4, definitely yes = 5) were used to
calculate means and standard deviations. In addition, they
were asked whether they would recommend such a therapy
for a spouse or sibling with the disease in question. Some
subjects cited their gender as an explanation for their failure
to respond to some questions, but at least 48 physicians
responded to each case. For ease of analysis, the results were
expressed on a three part scale ('definitely or probably no',
'uncertain', 'definitely or probably yes').
Fifteen questions were related to the administration of
chemotherapy (Table 2a), 15 to radiation therapy (Table Ilb)
and three to an experimental treatment, intravenous inter-
leukin-2 (without concomitant cellular therapy). Differences
among specialists were compared with analysis of variance
(ANOVA) and the specialists' mean scores compared with an
unpaired t-test.
Results
Oncologists willingness to undergo anti-cancer therapies
The subjects' responses to questions asking whether they
would undertake chemotherapy and radiotherapy themselves
for a variety of malignancies is shown in Tables hIa and Ilb.
While in some cases the great majority of physicians were
clearly willing or unwilling to undergo a given therapy, in
many others the responses failed to establish a group
opinion, here called 'agreement'. If, for example, the criterion
for 'agreement' requires that at least 70% of the respondents
accept or decline therapy, consensus is reached in 21 of the
30 cases (70%). If the threshold is raised to 85%, 'agreement'
is reached in only 11 cases (37%). (Information to indicate
why physicians would not undergo a given form of therapy
was not gathered because of the length of the questionnaire.)
The heterogeneity of the responses indicates that there is a
substantial lack of agreement about the benefits of these
'standard' therapies, particularly in cases where palliation,
rather than cure, is the goal. Physicians were equally willing
to take therapy themselves or to recommend it for a spouse
or sibling.
Are there inter-specialty differences in oncologists' willingness
to undertake therapy?
Because their specialty orientation might affect oncologists'
views of the desirability of a given treatment modality, re-
sponses of each group of specialists to the cases were
examined. Analysis of variance (ANOVA) showed significant
differences in the mean scores of the specialists in three
radiotherapy and five chemotherapy cases (Table II).
To determine whether radiotherapists or chemotherapists
were more likely than their colleagues to choose therapies
that they administered, the mean scores of the different
specialists were compared (Table III). (Because three t-tests
were performed on a single data set, only P values <0.017
are considered to be statistically significant.) Radiation thera-
pists as a group differed significantly from one or both of the
other groups in three of 15 cases (limited stage small cell lung
cancer, resected colon cancer, ovarian cancer), but at a level
approaching statistical significance (0.017<P<0.05) in four
additional cases (non-small cell lung cancer, histiocytic lym-
phoma, gastric cancer, multiple myeloma). Radiation
therapist differed with surgical oncologists in each of the
three cases achieving statistical significance, but with the
medical oncologists in only one.
Medical oncologists differed significantly with one or both
groups in six of 15 cases. (In three additional cases, the P
value approached a significant value, 0.017<P<0.05.) In
five cases, the medical oncologists differed significantly with
both surgical and radiation oncologists, in two with the
radiation oncologists, and in four with the surgical onco-
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Table III Variations in mean scores ofoncologic specialistsa
Limited small cell cancer
Extensive small cell cancer
Lung (non-small cell)
cancer
Testicular cancer
Hodgkin's disease
Histiocytic lymphoma
Myeloma
Ovarian cancer
Leukemia
Limited small cell cancer
Lung (non-small cell
cancer)
Histiocytic lymphoma
Colon cancer
Gastric cancer
Pancreatic
Myeloma
Ovarian
Chemotherapy cases
Med v RT Med v Surg Med v Both
0.004 0.0002 0.001
NS NS 0.04
0.001 NS NS
NS
NS
0.02
NS
0.02
NS
0.03
0.006
0.0001
0.0002
0.02
0.03
NS
0.013
0.001
0.007
0.006
NS
Radiotherapy cases
RT v Surg RT v Med RT v Both
0.003 NS NS
NS 0.02 0.02
0.04
0.003
0.04
NS
0.02
0.0001
NS
0.0001
NS
NS
NS
0.02
NS
0.0001
0.03
0.03
NS
0.0002
RT = radiation oncologists; Med = medical oncologistis; Surg-
= surgical oncologists. ap values using 1-tailed unpaired t-test.
NS = P>0.05.
Oncologists' willingness to undertake an experimental therapy
Physicians may be called upon to enroll patients in clinical
trials, some of which involve the use of experimental thera-
pies. Patients considering experimental therapies may be
quite influenced by their physician's attitude towards such
approaches. In order to learn about the views of this group
of academic physicians towards on experimental therapy, the
subjects were asked to consider whether they would undergo
intravenous infusions of interleukin-2 (administered as a
single agent without concomitant cellular therapy) for them-
selves or a spouse or sibling if diagnosed with one of three
forms of cancer. (A paper appearing a short time before had
reported responses to this form of therapy in 50% of mela-
noma patients treated, but in no patients with colon cancer
(Lotze et al., 1986). No information was given about patients
with renal cell carcinoma in that paper, although they were
known to respond to combined therapy with lymphoctes and
interleukin-2.)
As shown in Table IV, oncologists were more willing to
consider interleukin-2 if they had melanoma or renal cell
carcinoma than if they had colon carcinoma, even though no
good alternative curative therapy existed. In each case how-
ever, they were less likely to take the therapy themselves than
recommend it for a spouse or sibling, as determined either by
comparing the mean scores of their responses, or the propor-
tion responding in each of the three major response cate-
gories. There were no significant differences found among the
sub-speciality groups. Thus, oncologists did not embrace this
experimental therapy, even in the absence of a good alterna-
tive, despite one encouraging preliminary report in a major
medical journal.
Discussion
Situations that call for decisions to be made about admin-
istering anti-cancer therapies are stressful for patients and
physicians. Particularly when the treatment is administered
with palliative intent, as it is for many, the personal values of
patient and physician may be of great importance in reaching
a decision about whether to proceed with therapy.
Since physicians are among the most knowledgeable con-
sumers of health care, analysis of their personal health prac-
tices and attitudes may be of some interest. In one study, for
example, Bunker and colleagues, showed a higher rate of
Table IV Would oncologists recommend experimental therapy?
Probably or Probably or
Mean definitely no Uncertain definitely yes
(SD)
Metastatic melanoma
Self 2.90 (1.40)
Spouse/ 3.20 (1.13)
sibling
P = 0.008a
Metastatic renal cell carcinoma
Self 3.20 (1.39)
Spouse/ 3.43 (1.04)
sibling
P = 0.013a
Metastatic colonic carcinoma
Self 2.16 (1.08)
Spouse/ 2.41 (1.04)
sibling
P = 0.026a
Per cent ofoncologists
41 18 41
29 24 47
P = 0.027 (X2 = 7.23)
33
24
14 53
22 55
P= 0.042 (X2 = 6.36)
69 14
57 23
17
20
P = 0.039 (X2 = 6.50)
a2-tailed t-test.
utilisation of surgical services by physicians and their spouses
than by the general population (Bunker & Brown, 1974).
Since we could not determine directly how physicians are
treated when they have cancer, we chose to learn how they
think about treatment options. To maximise the chances that
the subjects had previously considered cancer treatments and
would be able to respond without needing to research the
subject, we asked a multi-disciplinary group of university
oncologists how they would proceed if they had cancer. We
found that they failed to reach a consensus for many forms
of cancer. Assuming that their working environments and
professional contacts allowed them to share a common
knowledge base, this finding suggests that personal values
may play a role in acceptance of therapy among this know-
ledgeable group of physicians.
Oncologists differ in their willingness to take anti-cancer
therapies
The method we used, developed without knowledge of simi-
lar efforts (Mackillop et al., 1987; Moore et al., 1988) was
designed to: (1) gather opinions from physicians who had not
been prepared or warned about the questions they would be
asked (unlike consensus conferences); (2) keep physicians
from comparing their responses to those expected or offered
by their colleagues (unlike the Delphi technique); (3) present
the subjects with a diverse group of clinical situations that
represent the range of malignancies seen in practice; (4)
ascertain a broad overview and avoid the biases of experts
considering questions of personal professional importance (as
occurs with some expert panels); and (5) integrate the
physicians' medical knolwedge and personal values by per-
sonalising the cases.
In only 37% of the cases presented did 85% or more of
the oncologists agree that they would accept or reject the
treatment in question. (The details of the chemotherapy or
radiotherapy treatments were not specified to avoid evoking
controversy over details which vary from one hospital to
another.) The range of responses indicates that the subjects
considered each case on the basis of its own natural history
and response to treatment. Overall, this particular mix of
cases and therapies elicited a large proportion of negative
responses ('definitely' or 'probably no'). While this fraction
would likely vary with the case mix presented, the heterogen-
eous responses serve to demonstrate that despite the number
of cases presented, the subjects discriminanted both among
the cases and between the therapies. Perhaps more impor-
tantly, the oncologists sampled neither simply accepted nor
rejected therapies on a wholesale basis. Even though onco-
logists must both face the limitations of the available
therapies every day and convince reluctant patients to con-
sider them, they as a group are neither 'true believers' or
nihilists.394 S.E. LIND et al.
Specialists' attitudes towards standard andexperimental
anti-cancer therapies
The results reported here confirm and extend previous work
in this area. Previously, physicians were asked about their
treatment preferences given a number of detailed clinical
scenarios involving either lung or genitourinary cancer. Both
surveys were conducted by mail rather than in person (there-
by enrolling a larger number of subjects at the cost of a
response rate of approximately 70%), and involved physic-
ians who treat cancer patients frequently but were not neces-
sarily certified as oncologists.
One hundred and eighteen Canadian physicians were asked
about their preferences for treatment if they were to be
diagnosed with non-small cell lung cancer (Mackillop et al.,
1987). Although 96% agreed they would opt for surgery
(with or without radiotherapy or chemotherapy) if they had
early, operable (i.e. potentially curable) lung cancer, con-
siderable variation in these experts' opinions was evident
when cure was not possible. If the disease was more locally
advanced, only 67% said they would elected a standard
therapy (i.e. radiotherapy, with or without chemotherapy or
surgery). Twenty-two per cent (the next largest group) said
they would elect no treatment. If faced with only the possi-
bility of an incomplete resection, 23% said they would elect
not to take any specific cancer treatment. Similarly, 20% of
those contemplating the treatment of painful bone metastases
indicated a preference for symptomatic measures alone, de-
clining the possibility of chemotherapy and/or radiotherapy.
The authors points out that although textbooks advocate
chemotherapy for this disease, few of the physicians surveyed
would wish this treatment for themselves.
A questionnaire mailed to specialists in genitourinary (GU)
oncology residing in Britain, Canada and the United States
asked them to consider how they would wish to be treated
for each of six different types of GU malignancy (Moore et
al., 1988). In only one case did more than 50% of the 153
respondents agree on which treatment modality they would
elect. Despite the lack of agreement about how to treat these
forms of malignancy, only 36% overal indicated they would
enter themselves in clinical trials. The authors conclude: 'The
bias of individual physicians presents a major limitation to
the conduct of clinical trials that address important areas of
controversy.'
The present study complements and extends these reports
insofar as it employs a similar surrogate methodology to
show that the lack of agreement among cancer specialists is
not limited to clinical scenarios involving lung or genitour-
inary cancer. As a result, more intensive efforts to examine
differences in physicians opinion about the worth of anti-
cancer therapies are warranted. Such efforts should ulti-
mately examine the attitudes of physicians who are not
oncologists. Such research may be helpful in understanding
patterns ofdelivery of treatment for cancer patients, and may
aid the national effort to increase patient enrollment in
clinical trials, If, for example, physicians more or less likely
to enroll patients in clinical trials (Hunter et al., 1987) could
be identified by this technique, resources could be directed
towards aiding them in these efforts. If, on the other hand,
subsets of physicians who are likely to participate cannot be
defined, funds might better be spent informing patients of the
uncertainties of current therapies. This work also serves to
reinforce and extend the findings of Taylor et al. (1984),
insofar as it suggests that physician opinion and preference
based upon personal, non-professional values and opinions
may be major determinants of professional behaviour.
Surgical oncologists differed more often with the 'treating'
group of specialists than did the other 'non-treating' specia-
list group for both the chemotherapy and radiation therapy
cases. In each case, surgical oncologists were less inclined to
accept therapy than the 'treating' specialists. This may be
due, in the case of haematologic malignances, to a lack of
familiarity with the subject. Alternatively, surgeons may
simply be generally opposed to non-surgical therapies, but is
seems more likely still that they view the risk:benefit ratio of
chemotherapy and radiotherapy differently than do their col-
leagues. They may underestimate treatment benefits in rela-
tion to other types of oncologists, or place a higher value on
avoiding risks and side effects than do others, either because
of their innate values or simply because they see only those
patients who experience serious side effects from these other
forms of therapy. Might these differing views make a differ-
ence? If surgeons refer patients to other oncology specialists
as a matter of routine, regardless of whether they would elect
therapy for themselves, clinical care is unlikely to be affected.
If on the other hand, their views affect their referral patterns,
such opinions may play a role in determining the pattern of
care delivered to their patients.
That oncologists were less willing to take an experimental
therapy themselves than recommend it for a spouse is provo-
cative, but must be viewed with caution at this time, for the
results may have statistical, but not 'clinical' significance.
Because efforts were not undertaken to ascertain the specific
reasons for this difference, the finding should simply be used
as a starting point for future study.
Using expert opinion to define clinical uncertainty
It may be helpful at times to define areas where physicians
disagree (perhaps using a method similar to the one described
here), in order to define areas where uncertainty might be
resolved by careful clinical research. Freedman points out
that a physician may not ethically recommend participation
in a trial if he or she feels that one arm is superior to another
(Freedman, 1987). He suggests that the ethical basis for
conducting a trial may be documented if the opinion of the
expert medical community indicates that there is uncertainty
about which arm is superior (which he calls 'clinical equi-
poise'), thus taking the burden of making this decision off the
shoulders of each individual physician, who may not be
familiar with all the relevant data. He does not, however,
indicate how the opinion of the expert medical community
may be established. Data, such as that reported here, which
shows that experts have not reached a consensus about a
treatment, may be used to document such uncertainty and
may be used to recruit physicians to participate in trials when
they might otherwise be hesitant to do so.
Limitations ofthe current study andfuture directions
This study was prompted in part by the comments of physi-
cians (non-oncologists) who said they would not undergo
certain anti-cancer therapies if diagnosed with cancer. Intri-
gued by these comments, we sought to determine in a pilot
study whether oncologists shared this view, because of the
implications for patient treatment. Unfortunately, we were
not able to ascertain the reasons for the differences in re-
sponses, and will need to explore this in future studies.
This study, although limited in several respects, indicates
that there is indeed considerable disagreement among onco-
logists in this regard, and points to future investigations, in
part because the size and composition of the sample studied
does not allow for broad generalisations to be made. The
physicians involved, although representing all three major
branches of oncology, were all working at academic institu-
tions affiliated with a single medical school, and represent
those willing to participate in this study. They thus are not a
representative group of American oncologists. The findings
reported here, however, indicate that efforts to survey a
larger group of both oncologic and non-oncologic physicians
appear to be justified, and might be undertaken with the
cooperation of professional medical societies. Such studies
should seek to explore the reasons for the responses given, as
well as corrobarate and extend these findings. Future efforts
should also attempt to determine whether the differences in
physician opinions actually influence the rates of administra-
tion of anti-cancer therapies.
The authors gratefully acknowledge the cooperation of the physi-
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